Source: Fox News
Summary
Bunnie XO, also known as Alyssa DeFord, shared her experience with a weight-loss medication called retatrutide, which is currently undergoing clinical trials. After taking the drug, she reported feeling intense depression and emotional numbness, describing her mental state as “dark.” Following her decision to stop the medication, she noted improvements in her mood. Lilly, the drug’s manufacturer, emphasized that retatrutide is not approved for general use and warned about the dangers of unregulated medications. Experts are cautioning against the use of these drugs outside of clinical trials due to potential psychiatric risks.
Our Reading
This is not the first time this advice has been updated. Bunnie’s case follows a familiar trend where weight-loss drugs enter the market amid uncertainty and varying outcomes. Though the drug is still in trials, cautionary statements from experts echo the warnings seen in previous iterations of weight-loss treatments. Terms like “potential link” and “awaiting further studies” surface as familiar refrains. While individual experiences vary, the juxtaposition of weight loss and mental health struggles remains a common thread. Engaging with these medications seems to invite both hope and concern. Monitoring will continue.
Author: Evan Null
